Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Promegestone, a new progestin].

J P Raynaud, T Ojasoo

    Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Promegestone (R 5020) is a potent progestin with anti-estrogenic effects. Clinical trials show it is significantly more effective than dydrogesterone for luteal insufficiency, suggesting promise in cancer therapy and psychiatry.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Protection of patients against violence in medical institutions and the need for general safeguarding measures.

    European child & adolescent psychiatry·2022
    Same author

    [COVID 19: How does child psychiatry adapt in these times of adversity?]

    Neuropsychiatrie de l'enfance et de l'adolescence·2020
    Same author

    [Early restrictive feeding disorders: Quantitative assessment of parent/infant feeding interactions].

    L'Encephale·2016
    Same author

    Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function.

    Journal of attention disorders·2013
    Same author

    [Self-evaluation of the quality of life of children aged 6 to 12 years old: construction and first steps in the validation of kidlQol, a generic computer-based tool].

    Sante publique (Vandoeuvre-les-Nancy, France)·2005
    Same author

    [Self-evaluation of the quality of life of children aged 6 to 12 years old: analysis of the concept and development of a prototype tool].

    Sante publique (Vandoeuvre-les-Nancy, France)·2005
    Same journal

    [Neuroprotection for preterm infants with antenatal magnesium sulphate].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified?]

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Lifestyle recommendations for prevention of spontaneous preterm birth in asymptomatic pregnant women].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Guidelines for clinical practice: Prevention of spontaneous preterm birth (excluding preterm premature rupture of membranes) - Introduction].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2017
    Same journal

    [Psychological aspects of abortion].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2016
    Same journal

    [Induced abortion: Guidelines for clinical practice - Introduction].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2016
    See all related articles

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Oncology
    • Psychiatry

    Background:

    • Promegestone (R 5020) is a widely used radioligand for the progestin receptor.
    • It exhibits potent progestin activity without androgenic side-effects and possesses significant anti-estrogenic properties.

    Purpose of the Study:

    • To describe the biological activities of promegestone.
    • To evaluate its therapeutic effectiveness in luteal insufficiency.
    • To explore its potential applications in hormone-dependent breast cancer and psychiatric disorders.

    Main Methods:

    • Review of pharmacological data on promegestone.
    • A double-blind clinical trial comparing promegestone (0.125-0.250 mg) with dydrogesterone (10-20 mg) for luteal insufficiency.

    Related Experiment Videos

    Main Results:

    • Promegestone demonstrated significantly superior potency (p < 0.001) compared to dydrogesterone in treating luteal insufficiency.
    • Pharmacological profile indicates potential for treating hormone-dependent breast cancer and psychological disorders associated with premenstrual syndrome and perimenopause.

    Conclusions:

    • Promegestone is a highly potent progestin with a favorable side-effect profile.
    • Its efficacy in luteal insufficiency is clinically established.
    • Promegestone shows promise for expanded therapeutic applications in oncology and psychiatry.